Intravenous therapies
NAD (nicotinamide adenine dinucleotide) is a coenzyme essential for cellular metabolism, present in the body in two main forms: NAD+ (the oxidized form) and NADH (the reduced form).
NAD+ and NADH take part in the cellular reactions through which nutrients are converted into energy, by transferring electrons between different metabolic processes. NAD+, the oxidized form, additionally plays an important role as a substrate for enzymes involved in DNA repair, the cellular stress response and metabolic regulation.
Through these functions, NAD+ metabolism is closely linked to mitochondrial function, cellular energy production and the maintenance of cellular homeostasis, representing an important field of research in the biology of aging and in longevity medicine.
At Maison Longévité, intravenous NAD+ administration is integrated into a cautious and personalized medical approach, following an assessment of health status, metabolic profile and individual medical objectives.
With advancing age, changes may occur in NAD+ metabolism, associated with processes such as mitochondrial dysfunction, oxidative stress, metabolic changes and altered cellular repair mechanisms.
Current research shows that the relationship between NAD+, age and human health is complex. NAD+ levels and metabolism may vary depending on tissue, age, metabolic status, lifestyle and the presence of certain pathologies.
NAD+ administration is therefore approached as a possible adjuvant therapy, used selectively and integrated into an individualized medical strategy for healthy aging and longevity.
NAD+ takes part in two major categories of biological processes:
Through the reversible conversion between NAD+ and NADH, this system takes part in the oxidation–reduction reactions by which energy derived from nutrients is transferred and used by cells, including in the mitochondrial processes involved in ATP production.
NAD+ also acts as a substrate for enzymes such as sirtuins and PARP, involved in metabolic regulation, the cellular stress response, DNA repair and the maintenance of genomic stability.
These mechanisms explain the scientific interest in NAD+ metabolism in research on the biological processes associated with aging.
The biological role of NAD+ is well documented, and clinical research into ways of influencing NAD+ metabolism has developed considerably in recent years.
An important part of the human studies has focused on NAD+ precursors, such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). There are also human studies that have evaluated the direct intravenous administration of NAD+, providing information on its metabolism and tolerability.
However, the data available for intravenous NAD+ are more limited than the literature on NAD+ precursors, and the results of studies with NR or NMN cannot be automatically extrapolated to intravenous NAD+ administration.
Research continues to evaluate the potential of strategies for modulating NAD+ metabolism in the context of metabolic health, cellular function and the biological processes associated with aging.
Following medical assessment, NAD+ administration may be considered in certain selected contexts, such as:
These situations do not represent universal indications. The indication is established individually, following consultation and medical assessment.
NAD+ is administered intravenously, slowly and under medical supervision.
The dose and the rate of administration are established individually and may be adjusted according to the patient's clinical profile and tolerance. Slow administration contributes to better tolerability of the infusion, and the duration of a session varies depending on dose, protocol and individual response.
At Maison Longévité, NAD+ therapy is carried out under the coordination of a physician with specific international training in NAD+ infusion therapy, with an emphasis on patient selection, individualization of the protocol, monitoring and safety.
The available clinical data provide information on the metabolism and tolerability of intravenous administration, while the long-term safety profile and clinical effects require evaluation through larger studies.
Before therapy is initiated, the following are assessed:
When the clinical context requires it, the assessment may be completed with additional tests or investigations.
NAD+ administration requires individual medical assessment and may be contraindicated, postponed or may require additional precautions in certain clinical situations.
These may include:
The decision to administer belongs to the physician and is based on an individual assessment of the benefit–risk ratio.
NAD+ does not replace the fundamental interventions that influence long-term health.
Physical activity, maintaining muscle mass, sleep, nutrition, metabolic and cardiovascular health, prevention and the control of risk factors remain the central elements of longevity medicine.
At Maison Longévité, NAD+ administration may complement these interventions when medical assessment indicates that integrating it into an individualized program is appropriate.
NAD+ metabolism is intensively studied in the biology of aging. Its role in energy metabolism, mitochondrial function, DNA repair and the activity of NAD+-dependent enzymes is well documented.
Human studies have shown that NAD+ metabolism can be influenced through different strategies, and research continues to investigate their implications for metabolic function, cellular health and the processes associated with aging.
For the direct intravenous administration of NAD+ there are human data on the metabolism and tolerability of the infusion, but clinical evidence regarding long-term benefits is still developing.
This difference between the well-documented biological mechanisms and the current level of clinical evidence for intravenous administration underlies the cautious and individualized medical approach adopted at Maison Longévité.
At Maison Longévité, NAD+ therapy is recommended only following medical assessment and is administered within an individualized protocol, with monitoring of tolerability and adaptation of the dose and rate of administration according to each patient's profile.
Medical content written and reviewed by Dr. Mihaela Marinescu — Specialist in Geriatrics and Gerontology · Medical Director, Maison Longévité. Last reviewed: 7 October 2026. Meet the medical team
This page is for information and education. It does not replace a medical consultation or the individual recommendations of a healthcare professional.
Questions and answers
Book consultation
Fill in the form below and we will contact you to arrange the details of your appointment.
